Selected research
Industry Research
Antibody-drug Conjugate for Cancer Industry Research Report 2026
Market perspective
The global Antibody-drug Conjugate for Cancer market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Antibody-drug Conjugate for Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antibody-drug Conjugate for Cancer market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antibody-drug Conjugate for Cancer market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antibody-drug Conjugate for Cancer include Gilead Sciences, Innate Pharma, Rakuten Medical, Seagen, AstraZeneca, GSK, Pfizer, Roche and Takeda. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Antibody-drug Conjugate for Cancer market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antibody-drug Conjugate for Cancer.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antibody-drug Conjugate for Cancer Market by Company
Gilead Sciences
Innate Pharma
Rakuten Medical
Seagen
AstraZeneca
GSK
Pfizer
Roche
Takeda
Antibody-drug Conjugate for Cancer Segment by Type
Hematological Malignancies Drugs
Solid Tumor Drugs
Antibody-drug Conjugate for Cancer Segment by Application
Hospital
Pharmacy
Other
Antibody-drug Conjugate for Cancer Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugate for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugate for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugate for Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antibody-drug Conjugate for Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hematological Malignancies Drugs
- Solid Tumor Drugs
Applications
- Hospital
- Pharmacy
- Other
Companies covered
- Gilead Sciences
- Innate Pharma
- Rakuten Medical
- Seagen
- AstraZeneca
- GSK
- Pfizer
- Roche
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Antibody-drug Conjugate for Cancer by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Hematological Malignancies Drugs
- 2.2.3 Solid Tumor Drugs
- 2.3 Antibody-drug Conjugate for Cancer by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Antibody-drug Conjugate for Cancer Breakdown Data by Type
- 3.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Type (2021-2026)
- 3.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Type (2027-2032)
4 Antibody-drug Conjugate for Cancer Breakdown Data by Application
- 4.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Application (2021-2026)
- 4.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Antibody-drug Conjugate for Cancer Market Perspective (2021-2032)
- 5.2 Global Antibody-drug Conjugate for Cancer Growth Trends by Region
- 5.2.1 Global Antibody-drug Conjugate for Cancer Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Antibody-drug Conjugate for Cancer Historic Market Size by Region (2021-2026)
- 5.2.3 Antibody-drug Conjugate for Cancer Forecasted Market Size by Region (2027-2032)
- 5.3 Antibody-drug Conjugate for Cancer Market Dynamics
- 5.3.1 Antibody-drug Conjugate for Cancer Industry Trends
- 5.3.2 Antibody-drug Conjugate for Cancer Market Drivers
- 5.3.3 Antibody-drug Conjugate for Cancer Market Challenges
- 5.3.4 Antibody-drug Conjugate for Cancer Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Antibody-drug Conjugate for Cancer Players by Revenue
- 6.1.1 Global Top Antibody-drug Conjugate for Cancer Players by Revenue (2021-2026)
- 6.1.2 Global Antibody-drug Conjugate for Cancer Revenue Market Share by Players (2021-2026)
- 6.2 Global Antibody-drug Conjugate for Cancer Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Antibody-drug Conjugate for Cancer Head Office and Area Served
- 6.4 Global Antibody-drug Conjugate for Cancer Players, Product Type & Application
- 6.5 Global Antibody-drug Conjugate for Cancer Manufacturers Established Date
- 6.6 Global Antibody-drug Conjugate for Cancer Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Antibody-drug Conjugate for Cancer Market Size (2021-2032)
- 7.2 North America Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
- 7.4 North America Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Antibody-drug Conjugate for Cancer Market Size (2021-2032)
- 8.2 Europe Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
- 8.4 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size (2021-2032)
- 9.2 Asia-Pacific Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Antibody-drug Conjugate for Cancer Market Size (2021-2032)
- 10.2 South America Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
- 10.4 South America Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size (2021-2032)
- 11.2 Middle East & Africa Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Gilead Sciences
- 12.1.1 Gilead Sciences Company Information
- 12.1.2 Gilead Sciences Business Overview
- 12.1.3 Gilead Sciences Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026)
- 12.1.4 Gilead Sciences Antibody-drug Conjugate for Cancer Product Portfolio
- 12.1.5 Gilead Sciences Recent Developments
- 12.2 Innate Pharma
- 12.2.1 Innate Pharma Company Information
- 12.2.2 Innate Pharma Business Overview
- 12.2.3 Innate Pharma Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026)
- 12.2.4 Innate Pharma Antibody-drug Conjugate for Cancer Product Portfolio
- 12.2.5 Innate Pharma Recent Developments
- 12.3 Rakuten Medical
- 12.3.1 Rakuten Medical Company Information
- 12.3.2 Rakuten Medical Business Overview
- 12.3.3 Rakuten Medical Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026)
- 12.3.4 Rakuten Medical Antibody-drug Conjugate for Cancer Product Portfolio
- 12.3.5 Rakuten Medical Recent Developments
- 12.4 Seagen
- 12.4.1 Seagen Company Information
- 12.4.2 Seagen Business Overview
- 12.4.3 Seagen Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026)
- 12.4.4 Seagen Antibody-drug Conjugate for Cancer Product Portfolio
- 12.4.5 Seagen Recent Developments
- 12.5 AstraZeneca
- 12.5.1 AstraZeneca Company Information
- 12.5.2 AstraZeneca Business Overview
- 12.5.3 AstraZeneca Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026)
- 12.5.4 AstraZeneca Antibody-drug Conjugate for Cancer Product Portfolio
- 12.5.5 AstraZeneca Recent Developments
- 12.6 GSK
- 12.6.1 GSK Company Information
- 12.6.2 GSK Business Overview
- 12.6.3 GSK Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026)
- 12.6.4 GSK Antibody-drug Conjugate for Cancer Product Portfolio
- 12.6.5 GSK Recent Developments
- 12.7 Pfizer
- 12.7.1 Pfizer Company Information
- 12.7.2 Pfizer Business Overview
- 12.7.3 Pfizer Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026)
- 12.7.4 Pfizer Antibody-drug Conjugate for Cancer Product Portfolio
- 12.7.5 Pfizer Recent Developments
- 12.8 Roche
- 12.8.1 Roche Company Information
- 12.8.2 Roche Business Overview
- 12.8.3 Roche Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026)
- 12.8.4 Roche Antibody-drug Conjugate for Cancer Product Portfolio
- 12.8.5 Roche Recent Developments
- 12.9 Takeda
- 12.9.1 Takeda Company Information
- 12.9.2 Takeda Business Overview
- 12.9.3 Takeda Revenue in Antibody-drug Conjugate for Cancer Business (2021-2026)
- 12.9.4 Takeda Antibody-drug Conjugate for Cancer Product Portfolio
- 12.9.5 Takeda Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst